Skip to main content

Table 1 Baseline characteristics of the study groupsa

From: Randomized supplementation of 4000 IU vitamin D3 daily vs placebo on the prevalence of anemia in advanced heart failure: the EVITA trial

Characteristics

Vitamin D 4000 IU (n = 85)

Placebo (n = 87)

P-Value

Females (%)

12.9

21.8

0.12

Age (years)

56 (49–61)

54 (47–59)

0.09

Anemic subjectsb (%)

17.2

10.6

0.19

BMI (kg/m2)

28.4 (25.0–31.4)

28.1 (25.7–32.2)

0.59

NYHA (%)

 Class II

77.6

71.3

0.34

 Class III

22.4

28.7

0.34

 LVEF (%)

30.0 (23.5–35.0)

28.0 (24.0–35.0)

0.96

 LVED (mm)

66.0 (59.0–73.0)

66.0 (60.0–75.0)

0.97

Primary Disease (%)

 Dilated cardiomyopathy

38.8

50.6

0.12

 Coronary heart disease

57.6

42.5

0.05

 Others

3.5

6.9

0.32

Comorbidities (%)

 Diabetes

28.2

16.1

0.06

 Arterial hypertension

25.9

29.9

0.56

 Renal insufficiency

10.6

8.0

0.57

Drug therapy (%)

 Loop diuretic

82.4

86.2

0.49

 Thiazide diuretic

25.9

31.0

0.45

 Aldosterone antagonist

81.2

86.2

0.37

 ACE- inhibitor

72.9

71.3

0.81

 AT II blocker

29.4

36.8

0.31

 Beta-blocker

96.5

97.7

0.63

 Digoxin

31.8

40.2

0.25

 Antiarrhythmic drug

24.7

28.7

0.55

 Lipid-lowering drug

57.6

54.0

0.63

 Calcium channel blocker

3.5

3.4

0.98

 Vitamin D supplement

0.0

0.0

> 0.999

Vitamin D metabolites

 25OHD (nmol/L)

30.7 (22.0–46.6)

34.4 (26.7–45.9)

0.37

 1,25(OH)2D (pmol/L)c

81.6 (60.8–100.9)

87.7 (65.2–104.8)

0.18

Hematological parameters

 Hemoglobin (g/dL)

14.2 ± 1.6

14.2 ± 1.5

0.97

 Hematocrit (%)

42.2 ± 4.9

42.2 ± 4.2

0.93

 Leukocytes (109/L)

8.1 (6.8–9.6)

7.7 (6.2–9.6)

0.37

 Erythrocytes (1012/L)

4.7 (4.4–5.0)

4.6 (4.3–4.9)

0.42

 MCV (μm3)

90.6 (88.1–93.4)

92.9 (90.1–95.6)

0.01

 MCH (pg Hb/red blood cell)

30.7 ± 2.0

31.2 ± 2.5

0.10

 MCHC (g/L)

33.6 (33.0–34.8)

33.9 (33.0–34.7)

0.87

 RDW (%)

12.7 (11.9–13.5)

12.5 (11.9–13.2)

0.32

Additional parameters

 eGFR values

 ≥ 60 mL/min/1.73 m2 (%)

69.8

73.6

0.6

 < 60 mL/min/1.73 m2 (%)

30.2

26.4

0.62

 CRP (mg/dL)d

0.24 (0.10–0.69)

0.21 (0.09–0.40)

0.41

 BNP (pg/mL)e

270 (164–515)

248 (117–614)

0.96

 Calcium (mmol/L)

2.39 ± 0.12

2.38 ± 0.11

0.70

  1. BNP brain natriuretic peptide, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, eGFR estimated globular filtration rate, LVEF left ventricular ejection fraction, LVED left ventricular end-diastolic diameter, MCH mean corpuscular hemoglobin, MCV mean corpuscular volume, RDW red blood cell distribution width
  2. amedian and interquartile range, mean and SD, or percentage of observations, when appropriate
  3. bHemoglobin < 12.0 g/dL in females and < 13.0 g/dL in males
  4. cdata are based on 161 patients
  5. ddata are based on 155 patients
  6. edata are based on 115 patients
Back to article page

Nutrition Journal

ISSN: 1475-2891

Contact us